NEW YORK (GenomeWeb News) – Piper Jaffray today upgraded Pacific Biosciences to a Neutral rating after the next-generation sequencing company announced better than expected placements of its instruments.

The investment bank upgraded PacBio from its previous rating of Underweight, and raised the price target on its shares to $3.10 from $2.00.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.